Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

20    Forest Laboratories    $5.2B     up 10.6%
Global revenue*: $4.2B (20th); up 7.7%

R&D spend*: $716M (19th), down 34.9%; 17.0% of rev.

Top brands: Lexapro ($2.9B), Namenda ($1.5B), Bystolic ($383M)

Planned launches: Aclidinium (COPD), ­linaclotide (IBS)

Promotional spend: $866M (9th); 17.5% of rev.

Patent expirations: Lexapro (2012), Namenda (2015)

Forest's top-selling drug, $2.9-billion SSRI Lexapro, just lost patent protection, and number two drug Namenda's next in 2015. On the other other hand, there's the boffo sideshow that is longtime chief Howard Solomon's ongoing battles with (some would say persecution by) HHS and activist investor Carl Icahn. The upside is the company launched Teflaro in March, following Daliresp and Viibryd, and has already filed NDAs for aclidinium (COPD) and linaclotide (IBS).
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 20 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.